Clinical Study

Phase II Investigation Of Adjuvant Combined Cisplatin And Radiation With Pembrolizumab In Resected Hnscc

Posted Date: Nov 8, 2017

  • Investigator: Trisha Wise-Draper
  • Specialties: Hematology/Oncology, Oncology, Cancer, Radiation Oncology
  • Type of Study: Drug

The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates your immune system to fight your cancer) to treatment that you will already be getting for your cancer. You will be offered “standard of care” treatment whether you participate in this study or not. The standard of care treatment will include surgery followed by radiation for 6 weeks. You will also receive cisplatin as standard of care once a week for 6 weeks if your cancer is found to be “high risk”. High risk includes cancer that was not completely removed (positive margins) or cancer that has invaded through the outer lining of your lymph nodes. The risks and benefits of the standard of care treatment will be discussed by your regular doctor.

Criteria:

To Be Eligible For This Study, Patients Must Have Head And Neck Cancer That Requires Surgery As Well As Post-Operative Radiation And Possibly Cisplatin.

Keywords:

Cancer, Head And Neck, Hnscc, Resected, Ucci-Hn-15-01

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu